Autophagy-Lysosome Pathway in Neurodegeneration

Migration, Crosslink

📖

Autophagy-Lysosome Pathway in Neurodegeneration

active

wiki page Created: 2026-04-02T07:20:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-autophagy-lysosome-neuro

📖 Wiki Page

mechanism954 wordssynced 2026-04-02

Autophagy-Lysosome Pathway in Neurodegeneration

Overview

The autophagy-lysosome pathway (ALP) is a critical cellular degradation system that maintains neuronal homeostasis by clearing damaged organelles, protein aggregates, and pathogenic proteins. Dysfunction of this pathway is increasingly recognized as a central mechanism in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[@noda2018].

Introduction

Autophagy (from Greek "self-eating") is a highly conserved cellular process that delivers cytoplasmic components to lysosomes for degradation. In neurons—post-mitotic cells that cannot dilute damaged proteins through cell division—autophagy is particularly crucial for long-term survival[@mizushima2020][@chen2020].

There are three major forms of autophagy[@nixon2008]:

Macroautophagy — formation of double-membrane autophagosomes that fuse with lysosomes

Microautophagy — direct engulfment of cytoplasm by lysosomal invagination

Chaperone-mediated autophagy (CMA) — selective import of proteins containing KFERQ motif via LAMP-2A

Autophagy Machinery

Initiation

The initiation of autophagy is regulated by the ULK1 complex (ULK1/2, ATG13, FIP200, ATG101) which senses nutrient status and energy levels via AMPK activation and mTORC1 inhibition[@noda2018][@chesser2018].

Nucleation

...

Autophagy-Lysosome Pathway in Neurodegeneration

Overview

The autophagy-lysosome pathway (ALP) is a critical cellular degradation system that maintains neuronal homeostasis by clearing damaged organelles, protein aggregates, and pathogenic proteins. Dysfunction of this pathway is increasingly recognized as a central mechanism in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[@noda2018].

Introduction

Autophagy (from Greek "self-eating") is a highly conserved cellular process that delivers cytoplasmic components to lysosomes for degradation. In neurons—post-mitotic cells that cannot dilute damaged proteins through cell division—autophagy is particularly crucial for long-term survival[@mizushima2020][@chen2020].

There are three major forms of autophagy[@nixon2008]:

Macroautophagy — formation of double-membrane autophagosomes that fuse with lysosomes

Microautophagy — direct engulfment of cytoplasm by lysosomal invagination

Chaperone-mediated autophagy (CMA) — selective import of proteins containing KFERQ motif via LAMP-2A

Autophagy Machinery

Initiation

The initiation of autophagy is regulated by the ULK1 complex (ULK1/2, ATG13, FIP200, ATG101) which senses nutrient status and energy levels via AMPK activation and mTORC1 inhibition[@noda2018][@chesser2018].

Nucleation

The class III PI3K complex (BECN1, PIK3C3, PIK3R4, AMBRA1) generates phosphatidylinositol-3-phosphate (PI3P) at the phagophore assembly site (PAS), recruiting LC3-conjugation machinery[@xilouri2019].

Elongation and Closure

The ATG12-ATG5-ATG16L1 complex and LC3/GABARAP lipidation systems facilitate membrane expansion and closure of the autophagosome. Key proteins include:

[MAP1LC3A/B/C](/proteins/map1lc3a) (LC3)
[GABARAP](/genes/gabarap)
[ATG5](/proteins/atg5)
[ATG7](/proteins/atg7)
[ATG3](/genes/atg3)

Fusion with Lysosomes

Autophagosomes fuse with lysosomes via SNARE proteins (STX17, SNAP29, VAMP8), mediated by [BECN1](/genes/becn1) and the HOPS complex[@chen2020][@forlenza2020].

Autophagy in Alzheimer's Disease

Amyloid-β and Autophagy

Autophagy is significantly impaired in AD brains. Autophagic vacuoles accumulate in dystrophic neurites, representing failed degradation of [amyloid-beta](/proteins/amyloid-beta) and damaged organelles[@nixon2008]. Key mechanisms include:

mTORC1 hyperactivation — leads to ULK1 inhibition and reduced autophagosome formation
Beclin 1 deficiency — BECN1 is reduced in AD brains, impairing nucleation
Lysosomal dysfunction — cathepsin activity is impaired in AD lysosomes

Tau Pathology and Autophagy

Autophagy also plays a role in [tau](/proteins/tau) degradation. Both macroautophagy and CMA can degrade pathological tau species. Impairment of these pathways contributes to tau aggregation and neurofibrillary tangle formation[@chesser2018].

Autophagy in Parkinson's Disease

α-Synuclein and Autophagy

[Alpha-synuclein](/proteins/alpha-synuclein) (SNCA) is degraded by both macroautophagy and CMA. Mutations or overexpression of SNCA overwhelm these pathways, leading to toxic oligomer accumulation[@xilouri2019].

GBA1 mutations — reduce lysosomal glucocerebrosidase activity, impairing autophagy
LRRK2 mutations — affect lysosomal function and autophagic flux
PARKIN/PINK1 — mitophagy receptors damaged in familial PD

Mitophagy in PD

PINK1 and PARKIN regulate selective mitophagy of damaged mitochondria. Mutations in [PINK1](/genes/pink1) and [PARK2](/genes/parkin) (encoding parkin) cause early-onset familial PD by impairing mitophagy[@pickrell2015].

Mermaid diagram (expand to render)

Therapeutic Implications

Autophagy-Targeting Strategies

| Approach | Mechanism | Status |
|----------|-----------|--------|
| [mTOR](/mechanisms/mtor-signaling-pathway) inhibitors (rapamycin, everolimus) | Activate ULK1 complex | Clinical trials |
| BECN1 activators | Enhance nucleation | Preclinical |
| Lysosomal enhancers | Improve cathepsin activity | Research |
| CMA activators | Selective protein clearance | Research |

Clinical Trials

Rapamycin (sirolimus) — mTOR inhibition for AD (NCT04640095)
Everolimus — mTOR inhibition for PD dementia (NCT04072674)
Lithium — GSK3β inhibition with autophagy enhancement[@forlenza2020]

Genes and Proteins in Autophagy

Key autophagy-related genes frequently mutated in neurodegeneration:

[BECN1](/genes/becn1) — Beclin 1, autophagy initiation
[MAP1LC3A/B](/genes/map1lc3a) — LC3, autophagosome marker
[ATG5](/genes/atg5) — Autophagy protein 5
[ATG7](/genes/atg7) — Autophagy protein 7
[LAMP2](/genes/lamp2) — Lysosome-associated membrane protein 2 (CMA)
[PINK1](/genes/pink1) — PTEN-induced kinase 1 (mitophagy)
[PARK2](/genes/parkin) — Parkin RBR E3 ubiquitin protein ligase
[GBA1](/genes/gba1) — Glucocerebrosidase (lysosomal function)
[LRRK2](/genes/lrrk2) — Leucine-rich repeat kinase 2

Cross-References

[Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction-neurodegeneration) — mitophagy connections
[Protein Aggregation Comparison](/mechanisms/protein-aggregation-comparison) — aggregate clearance
[Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway) — PD-specific mechanisms
[Tau Pathology Pathway](/mechanisms/tau-pathology-pathway) — AD-specific mechanisms
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)

Autophagy Dysfunction in Alzheimer's Disease

Lysosomal Impairment

Bordi et al. (2020) demonstrated that autophagy is severely impaired in AD brains, with accumulation of autophagic vacuoles containing incompletely degraded substrates[@bordi2020]. This impairment precedes clinical symptoms and correlates with disease severity.

Amyloid and Tau Clearance

Boland et al. (2018) showed that autophagy participates in both amyloid-beta and tau clearance, and pharmacological enhancement of autophagy reduces pathological burden in mouse models[@boland2018].

Autophagy in Parkinson's Disease

PINK1/Parkin Pathway

De Vries et al. (2023) reviewed mitophagy mechanisms in PD, highlighting that PINK1 and Parkin mutations impair mitochondrial quality control leading to neuronal death[@deVries2023].

Alternative Pathways

Youle et al. (2019) described alternative mitophagy receptors (BNIP3, FUNDC1) that may compensate in PD when PINK1/Parkin are impaired[@youle2019].

Chaperone-Mediated Autophagy in Neurodegeneration

LAMP-2A

Mader et al. (2022) showed that CMA activity declines with age and in neurodegenerative disease, and enhancing LAMP-2A expression restores alpha-synuclein and tau clearance[@mader2022].

Therapeutic Modulation of Autophagy

Clinical Trials

Schneider et al. (2023) reviewed autophagy modulators in clinical trials, including lithium, rapamycin, and novel small molecules that enhance autophagic flux[@schneider2023].

Drug Candidates

| Agent | Mechanism | Status |
|-------|-----------|--------|
| Lithium | mTOR inhibition, GSK-3 inhibition | Phase III |
| Rapamycin | mTOR inhibition | Preclinical |
| Trehalose | TFEB activation | Preclinical |
| Novel TFEB agonists | Transcription factor activation | Discovery |

Research Gaps

Unresolved Questions

Cell-type specificity: Which cell types benefit most from autophagy enhancement?

Timing: When in disease course is intervention most effective?

Delivery: How to achieve brain-penetrant autophagy modulators?

Biomarkers: Are there reliable markers of autophagic flux in patients?

Pathway Diagram

The following diagram shows the key molecular relationships involving Autophagy-Lysosome Pathway in Neurodegeneration discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

mechanisms-autophagy-lysosome-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-autophagy-lysosome-neurodegeneration
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-100132932186
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-autophagy-lysosome-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

571

Outgoing

772

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Autophagy-Lysosome Pathway in Neurodegeneration

Autophagy-Lysosome Pathway in Neurodegeneration

Overview

Introduction

Autophagy Machinery

Initiation

Nucleation

Autophagy-Lysosome Pathway in Neurodegeneration

Overview

Introduction

Autophagy Machinery

Initiation

Nucleation

Elongation and Closure

Fusion with Lysosomes

Autophagy in Alzheimer's Disease

Amyloid-β and Autophagy

Tau Pathology and Autophagy

Autophagy in Parkinson's Disease

α-Synuclein and Autophagy

Mitophagy in PD

Therapeutic Implications

Autophagy-Targeting Strategies

Clinical Trials

Genes and Proteins in Autophagy

Cross-References

Autophagy Dysfunction in Alzheimer's Disease

Lysosomal Impairment

Amyloid and Tau Clearance

Autophagy in Parkinson's Disease

PINK1/Parkin Pathway

Alternative Pathways

Chaperone-Mediated Autophagy in Neurodegeneration

LAMP-2A

Therapeutic Modulation of Autophagy

Clinical Trials

Drug Candidates

Research Gaps

Unresolved Questions

See Also

Related Hypotheses

Pathway Diagram

💬 Discussion